This is a double-blind randomized controlled study. The study will last up to 16 weeks from the initial phone screen (it could take up to eight weeks to schedule and complete the initial screening process and schedule the 2 MRI visits). Once subjects have completed the screening process, they will begin the 8-week trial phase. Subjects will be assessed weekly throughout the study for efficacy and tolerability.
The investigators plan to recruit 80 participants with emotional dysregulation (ED) in the treatment arm. In addition, the investigators will aim to recruit 40age-, sex-, and parental-education matched participants without emotional dysregulation, and major psychopathology as Typically Developing (TD) control participants in the control arm.
Upon scheduling the baseline visit, only the emotional dysregulation (ED) participants will be randomized 1:1 to be exposed to NAC or placebo treatment for 8 weeks. Participants will complete baseline and post-treatment (endpoint) brain MRI acquisition. TD participants will complete the same screening and characterization process as the ED group and then will be invited to complete MRI eligibility screening and to be scanned twice, separated by an eight-week interval, but the TD will not complete the NAC treatment or receive a placebo. See Table 1 (Study Schema) for a complete list of characterization measures to be completed by each group.

Start Date01 Jan 2027

Sponsor / Collaborator

The Massachusetts General Hospital

[+1]

NCT06260566

/ Not yet recruitingPhase 1IIT

A Phase 1 Trial of Tolerability of Enteral N-Acetylcysteine in Infants

Biliary atresia (BA) is a neonatal liver disease characterized by impaired bile flow and is the most common indication for pediatric liver transplantation. BA can be treated with the Kasai portoenterostomy (KP), a procedure that attempts to restore bile flow and slow disease progression. However, success of the KP procedure is quite variable, and lack of adjuvant medical therapies following KP is a major gap in pediatric hepatology.
This study begins to explore oral N-acetylcysteine (NAC) as a potential medical therapy in BA by determining whether an oral formulation can be given to infants. The primary objective is to determine tolerability of the oral NAC formulation. The primary outcome is tolerating at least 3 out of 4 total doses without emesis. The Bayesian Optimal Interval Design (BOIN) trial design will be used to determine the maximum tolerated dose of oral NAC. Our secondary objective is to assess palatability of the oral NAC formulation by comparing facial expressions when taking oral NAC versus other medications commonly given to cholestatic infants.

Start Date01 Oct 2026

Sponsor / Collaborator

Baylor College of Medicine

[+1]

NCT07543458

/ Not yet recruitingPhase 3IIT

A Randomised Platform Trial to Evaluate Therapeutics in Patients With Moderate or Severe Dengue (DEN-HOST)

The purpose of this multi-site, factorial randomised, platform trial is to evaluate host-directed therapeutic agents in patients hospitalised with moderate and severe dengue virus infection. Our primary aim is to find safe and affordable therapeutics which prevent disease progression among those at high risk for severe dengue, and improve outcomes for those with established severe disease, thereby also reducing the substantial burden placed on health systems in dengue endemic regions.

Start Date01 Oct 2026

Sponsor / Collaborator

Oxford University Clinical Research Unit, Vietnam

[+8]

100 Clinical Results associated with Acetylcysteine

100 Translational Medicine associated with Acetylcysteine

100 Patents (Medical) associated with Acetylcysteine

33,503

Literatures (Medical) associated with Acetylcysteine

31 Dec 2026·Adipocyte

Lack of receptor for advanced glycation end products attenuates obesity-induced adipose tissue senescence in mice

Article

Author: Chen, Ni ; Ma, Xiaoyu ; Xu, Jin ; Li, Ziyu ; Wu, Jianbo ; Wu, Jiaqi ; You, Jingcan ; Du, Zuoqin ; Zhang, Tao

The receptor for advanced glycation end products (RAGE) and its ligands are critical drivers of adipose tissue inflammation. While RAGE expression increases in ageing cells and pathological conditions, its specific role in high-fat diet (HFD)-induced adipose tissue senescence remains to be fully elucidated. In this study, we investigated the function of RAGE in the development of adipose tissue senescence associated with obesity. We observed that HFD-fed RAGE-deficient (RAGE^-/-) mice exhibited significantly reduced body weight and adipocyte hypertrophy compared to wild-type (WT) controls. At the molecular level, RAGE^-/- mice displayed lower mRNA expression of cell cycle regulators and markers of the senescence-associated secretory phenotype. This anti-senescent phenotype was accompanied by decreased reactive oxygen species (ROS) production and elevated expression of anti-oxidant genes. Mechanistically, the lack of RAGE resulted in the upregulation of silent information regulator type 1 (SIRT1) in adipose tissues. Notably, the inhibition of SIRT1 reversed these anti-senescent effects and attenuated anti-oxidant gene expression in RAGE-deficient mice. Furthermore, while antioxidant treatment with N-acetylcysteine (NAC) reduced p53 in WT mice, it failed to fully suppress p16 and p21, whereas NAC treatment in RAGE^-/- mice significantly downregulated all senescence markers, suggesting a synergistic protective effect. In conclusion, our results demonstrated that RAGE deficiency improved anti-oxidant properties and prevents adipocyte senescence via the SIRT1 signalling pathway, highlighting a potential therapeutic target for obesity-associated tissue dysfunction.

31 Dec 2026·Journal of the International Society of Sports Nutrition

A comprehensive review of the physiology and evidence base to guide the use of ergogenic and medical supplements for enhanced cycling performance

Review

Author: Edwards, Sophie ; Prieto-Bellver, Gorka ; Cornelisse, Erik ; Rowland, Angela ; Rowland, Andrew ; Hopkins, Ashley M ; Karapetis, Christos S ; Menz, Bradley ; Wallen, Matthew P

BACKGROUND:

A growing body of evidence supports the use of supplements to enhance cycling performance through both direct and indirect mechanisms.

METHODS:

This review was informed by a structured literature search conducted in PubMed, Scopus and Web of Science for peer-reviewed studies published up to May 2025. Studies were included if they involved human participants, were published in English and evaluated outcomes related to endurance performance, recovery or physiological function.

RESULTS:

Direct enhancement with ergogenic supplements is primarily achieved via modulation of skeletal muscle energy metabolism. During exercise, adenosine triphosphate (ATP) resynthesis is driven by the phosphagen system, glycolysis, oxidative phosphorylation and beta-oxidation, with each system contributing according to the intensity and duration of the effort. Supplements such as beta-alanine, caffeine, carbohydrates, carnitine, creatine monohydrate, dietary nitrates, electrolytes, exogenous ketones, N-acetylcysteine and sodium bicarbonate support these energy systems by improving substrate utilization, buffering capacity, energy availability or resistance to fatigue. In addition to ergogenic supplements that directly enhance performance, medical supplements play an important indirect role by supporting bone health, connective tissue integrity, inflammation management, micronutrient status, muscle repair and gut function. Evidence-based options for cyclists include calcium, cherry juice, collagen, curcumin, iron, multivitamins, omega-3 fatty acids, pickle juice, probiotics, protein, vitamin C, vitamin D and zinc. Each contribute to either improved recovery, immune support or long-term physiological adaptation. Evidence quality varied substantially across supplements, with strongest support for Australian Institute of Sport (AIS) Group A compounds. The integration of physiological testing including assessments of maximal oxygen consumption (VO₂max), lactate threshold, metabolic substrate utilization and blood biomarkers may inform the development of individualized supplementation strategies tailored to training demands and competitive goals.

CONCLUSIONS:

This evidence-informed approach underscores the synergistic relationship between nutrition, training and performance optimization in cycling. Future research should explore personalized nutrition frameworks, interactions between multi-supplement protocols and the molecular mechanisms underpinning adaptation to endurance training and nutritional interventions.

01 Dec 2026·MOLECULAR BIOLOGY REPORTS

Excavatolide E triggers oxidative stress-associated apoptosis and DNA damage to inhibit bladder cancer cell proliferation

Article

Author: Yang, Che-Wei ; Chang, Hsueh-Wei ; Chang, Fang-Rong ; Yen, Chia-Hung ; Sheu, Jyh-Horng ; Chien, Tsu-Ming ; Yu, Szu-Yin

BACKGROUND:

Excavatolide E (EXCE), a biocompound extracted from the gorgonian octocoral Briareum excavatum, has received limited attention for its anticancer properties, especially in the context of bladder cancer.

METHODS:

Cell viability, flow cytometry, and Western blotting were performed to assess the antiproliferative effects and mechanisms against bladder cancer cells.

RESULTS:

In the present study, the impacts and mechanisms of EXCE's antiproliferative effects on bladder cancer cells were assessed, along with its impacts on normal cells. EXCE selectively inhibited proliferation of bladder cancer cells, as compared to normal cells, i.e., selectivity index > 2, and induced greater oxidative stress in bladder cancer cells than normal cells, regarding the induction of cellular and mitochondrial ROS, as well as the depletion of mitochondrial membrane potential. Moreover, EXCE triggered higher levels of apoptosis, both extrinsic and intrinsic caspase activation, and DNA damage in bladder cancer cells than in normal cell; these EXCE-triggered antiproliferative mechanisms were alleviated by N-acetylcysteine (NAC), a ROS inhibitor.

CONCLUSION:

Therefore, EXCE's antiproliferative activity offers a promising therapeutic approach for targeting bladder cancer cells by modulating oxidative stress, while preserving the safety of normal cells.

126

News (Medical) associated with Acetylcysteine

23 Apr 2026

·www.prnewswire.com

Apotex Announces Strategic Transaction with Cumberland Pharmaceuticals to Integrate their U.S. Branded Businesses

TORONTO, April 23, 2026 /PRNewswire/ - Apotex, the largest Canadian based pharmaceutical company, and Cumberland Pharmaceuticals Inc. ("Cumberland"), a U.S. based specialty pharmaceutical company, today announced that they have entered into a strategic transaction to integrate Cumberland's U.S. branded businesses into Apotex (the "Transaction"). Under the terms of the agreement, Apotex will add a portfolio of branded medicines to its US business. The Transaction is expected to significantly expand Apotex's U.S. specialty and hospital focused business with a diversified basket of products across acute care, oncology, infectious disease, and gastroenterology. Closing of the Transaction is subject to, among other things, the required approval of Cumberland's shareholders. "This Transaction will strengthen our ability to support patients in some of the most critical moments of their care journey," said Jeff Watson, President & CEO of Apotex. "As a Force for Health, we are committed to improving access to high-quality medicines and ensuring that patients, families, and clinicians have the specialty treatments they rely on. Integrating Cumberland's branded commercial business into the Apotex family will enhance our ability to deliver a meaningful health impact for patients across the United States." The portfolio includes well-established brands such as Kristalose®, Caldolor®, Sancuso®, Vibativ®, Acetadote®, Vaprisol®, and Talicia®, which are prescribed across hospitals, oncology, infectious disease, and gastroenterology settings. These differentiated products benefit from strong clinical data and offer opportunities for continued commercial growth and optimization under Apotex's ownership. The portfolio of brands is an excellent strategic fit for Apotex enabling it to bolster its longstanding relationships with institutional customers and providing an opportunity to grow its position in the institutional channel. "With this Transaction, we intend to expand our U.S. commercial footprint in hospital and specialty care" said Christine Baeder, President of U.S. and LATAM. "Most importantly, we believe this Transaction will strengthen our ability to support physicians and the patients they serve. By enhancing awareness, improving access, and ensuring continuity of supply, we continue to act as a Force for Health in every community we reach." "We believe the integration of these products into Apotex creates more critical mass to better support patient care," said A.J. Kazimi, Chief Executive Officer at Cumberland. "We look forward to working with Apotex to ensure a smooth and successful transition that will expand access for patients who can benefit from our medicines." Raymond James is acting as financial advisor to Apotex in connection with the Transaction. About Apotex Apotex is a Canadian-based global health company. We improve everyday access to affordable, innovative medicines and health products for millions of people around the world, with a broad portfolio of generic, biosimilar, and innovative branded pharmaceuticals, and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions. Learn more at About Cumberland Pharmaceuticals Cumberland Pharmaceuticals Inc. is the largest biopharmaceutical company founded and headquartered in Tennessee. The company is focused on providing unique products that improve the quality of patient care. Cumberland currently distributes a portfolio of FDA-approved specialty brands. The company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidate in patients with cardiomyopathy associated with Duchenne Muscular Dystrophy, Systemic Sclerosis and Idiopathic Pulmonary Fibrosis. For more information see SOURCE Apotex Inc. 21% more press release views with Request a Demo

Phase 2

16 Apr 2026

·www.prnewswire.com

CUMBERLAND PHARMACEUTICALS ANNOUNCES EXPANDED INDICATION FOR CALDOLOR® (IBUPROFEN) INJECTION AND LAUNCH OF NEW BRAND WEBSITE

A Safe and Effective Non-Opioid Pain Management Solution NASHVILLE, Tenn., April 16, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced it has received approval from the U.S. Food and Drug Administration (FDA) for an expanded indication for its Caldolor® (ibuprofen) Injection product. The indication now includes the management of postoperative pain, and the approval coincides with the launch of a newly designed website for healthcare professionals highlighting this advancement and the evolving role of non-opioid pain management. With this update, Caldolor is indicated for use in adult and pediatric patients ages 3 months and older for: Management of mild to moderate pain, including postoperative pain Management of moderate to severe pain, including postoperative pain, as an adjunct to opioid analgesics Reduction of fever This expanded labeling reinforces Caldolor's role as a versatile, non-opioid intravenous analgesic option for use in perioperative and acute care settings. Advancing Perioperative Pain Management The newly launched Caldolor website aligns with this expanded indication, featuring dedicated content on postoperative pain management and the importance of multimodal, opioid-sparing approaches. Postoperative pain remains a significant challenge across surgical setting, with a growing emphasis on reducing opioid exposure while maintaining effective pain control. The updated website provides healthcare professionals with resources that focus on: The role of IV non-opioid options like Caldolor in perioperative care Strategies to support opioid stewardship amid the ongoing opioid crisis Clinical data supporting safe and effective pain and fever management with Caldolor In addition to featuring the new postoperative pain indication, the website offers comprehensive information on safety, dosing, efficacy, and access with J-Code reimbursement support. The site reinforces Caldolor as " A Safe and Effective Non-Opioid Pain Management Solution." Healthcare professionals can explore the updated website and resources at , which includes full prescribing and safety information. For medical inquiries, contact [email protected]. For product access support, contact [email protected]. About Caldolor ® (ibuprofen) Injection Caldolor is indicated in adults and pediatric patients for the management of mild to moderate pain and management of moderate to severe pain, including postoperative pain management, as an adjunct to opioid analgesics, as well as the reduction of fever. It was the first FDA-approved intravenous therapy for fever. Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other non-steroidal anti-inflammatory drugs (NSAIDs) and patients with a history of asthma or other allergic type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. For full prescribing and safety information, including boxed warning, visit . About Cumberland Pharmaceuticals Cumberland Pharmaceuticals Inc. is the largest biopharmaceutical company founded and headquartered in Tennessee and is focused on providing unique products that improve the quality of patient care. The company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments. The company's portfolio of FDA-approved brands includes: Acetadote ® (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor ® (ibuprofen) injection, for the treatment of pain and fever; Kristalose ® (lactulose) oral, a prescription laxative, for the treatment of constipation; Sancuso ® (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol ® (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ ® (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Talicia ®(omeprazole magnesium, amoxicillin and rifabutin) oral capsule, for the treatment of H. pylori infection. The company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidate in patients with cardiomyopathy associated with Duchenne Muscular Dystrophy, Systemic Sclerosis and Idiopathic Pulmonary Fibrosis. For more information on Cumberland's approved products, including full prescribing information, please visit links to the individual product websites, which can be found on the company's website . Forward-Looking Statements This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of Cumberland's operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland's results of operations. These factors include market conditions, competition, an inability of manufacturers to produce Cumberland's products on a timely basis or failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, maintaining an effective sales and marketing infrastructure, natural disasters, public health epidemics, and other events beyond our control, as more fully discussed in the Company's most recent Form 10-K and subsequent 10-Qs as filed with the SEC. There can be no assurance that results anticipated by the Company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof. SOURCE Cumberland Pharmaceuticals Inc. 21% more press release views with Request a Demo

Drug ApprovalPhase 2

16 Apr 2026

·investor.cumberlandpharma.com

CUMBERLAND PHARMACEUTICALS ANNOUNCES EXPANDED INDICATION FOR CALDOLOR® (IBUPROFEN) INJECTION AND LAUNCH OF NEW BRAND WEBSITE

A Safe and Effective Non-Opioid Pain Management Solution NASHVILLE, Tenn. , April 16, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced it has received approval from the U.S. Food and Drug Administration (FDA) for an expanded indication for its Caldolor® (ibuprofen) Injection product. The indication now includes the management of postoperative pain, and the approval coincides with the launch of a newly designed website for healthcare professionals highlighting this advancement and the evolving role of non-opioid pain management. With this update, Caldolor is indicated for use in adult and pediatric patients ages 3 months and older for: Management of mild to moderate pain, including postoperative pain Management of moderate to severe pain, including postoperative pain, as an adjunct to opioid analgesics Reduction of fever This expanded labeling reinforces Caldolor's role as a versatile, non-opioid intravenous analgesic option for use in perioperative and acute care settings. Advancing Perioperative Pain Management The newly launched Caldolor website aligns with this expanded indication, featuring dedicated content on postoperative pain management and the importance of multimodal, opioid-sparing approaches. Postoperative pain remains a significant challenge across surgical setting, with a growing emphasis on reducing opioid exposure while maintaining effective pain control. The updated website provides healthcare professionals with resources that focus on: The role of IV non-opioid options like Caldolor in perioperative care Strategies to support opioid stewardship amid the ongoing opioid crisis Clinical data supporting safe and effective pain and fever management with Caldolor In addition to featuring the new postoperative pain indication, the website offers comprehensive information on safety, dosing, efficacy, and access with J-Code reimbursement support. The site reinforces Caldolor as "A Safe and Effective Non-Opioid Pain Management Solution." Healthcare professionals can explore the updated website and resources at www.caldolor.com, which includes full prescribing and safety information. For medical inquiries, contact MSLsupport@cumberlandpharma.com. For product access support, contact orders@cumberlandpharma.com. About Caldolor® (ibuprofen) InjectionCaldolor is indicated in adults and pediatric patients for the management of mild to moderate pain and management of moderate to severe pain, including postoperative pain management, as an adjunct to opioid analgesics, as well as the reduction of fever. It was the first FDA-approved intravenous therapy for fever. Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other non-steroidal anti-inflammatory drugs (NSAIDs) and patients with a history of asthma or other allergic type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. For full prescribing and safety information, including boxed warning, visit www.caldolor.com. About Cumberland Pharmaceuticals Cumberland Pharmaceuticals Inc. is the largest biopharmaceutical company founded and headquartered in Tennessee and is focused on providing unique products that improve the quality of patient care. The company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments. The company's portfolio of FDA-approved brands includes: Acetadote® (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor® (ibuprofen) injection, for the treatment of pain and fever; Kristalose® (lactulose) oral, a prescription laxative, for the treatment of constipation; Sancuso® (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol® (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ® (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Talicia®(omeprazole magnesium, amoxicillin and rifabutin) oral capsule, for the treatment of H. pylori infection. The company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidate in patients with cardiomyopathy associated with Duchenne Muscular Dystrophy, Systemic Sclerosis and Idiopathic Pulmonary Fibrosis. For more information on Cumberland's approved products, including full prescribing information, please visit links to the individual product websites, which can be found on the company's website www.cumberlandpharma.com. Forward-Looking StatementsThis press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of Cumberland's operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland's results of operations. These factors include market conditions, competition, an inability of manufacturers to produce Cumberland's products on a timely basis or failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, maintaining an effective sales and marketing infrastructure, natural disasters, public health epidemics, and other events beyond our control, as more fully discussed in the Company's most recent Form 10-K and subsequent 10-Qs as filed with the SEC . There can be no assurance that results anticipated by the Company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof. View original content:https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-announces-expanded-indication-for-caldolor-ibuprofen-injection--and-launch-of-new-brand-website-302744319.html SOURCE Cumberland Pharmaceuticals Inc. Shayla Simpson, Cumberland Pharmaceuticals Inc., (615) 255-0068; Emily Kent, Dalton Agency, (540) 621-5448

Drug ApprovalPhase 2

100 Deals associated with Acetylcysteine

External Link

KEGG	Wiki	ATC	Drug Bank
D00221	Acetylcysteine	V03AB23 S01XA08 R05CB01	DB06151

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Bronchitis	China	Parexel China Co.,Ltd.	13 May 2025
Nails, Ingrown	Japan	Maruho Co., Ltd.	27 Mar 2023
Acetaminophen overdose	Australia	Pfizer Australia Pty Ltd.	17 Jul 2006
Pulmonary Disease, Chronic Obstructive	China	Jiangsu Jibeier Pharmaceutical Co. Ltd.	01 Jan 1985
Asthma	Japan	Sannova KK	05 Jan 1965
Bronchiectasis	Japan	Sannova KK	05 Jan 1965
Bronchitis, Chronic	Japan	Sannova KK	05 Jan 1965
Cystic Fibrosis	Japan	Sannova KK	05 Jan 1965
Laryngitis	Japan	Sannova KK	05 Jan 1965
Pharyngitis	Japan	Sannova KK	05 Jan 1965
Pneumonia	Japan	Sannova KK	05 Jan 1965
Pulmonary Emphysema	Japan	Sannova KK	05 Jan 1965
Pulmonary Tuberculosis	Japan	Sannova KK	05 Jan 1965
Chemical and Drug Induced Liver Injury	United States	Apothecon LLC	14 Sep 1963
Liver Injury	United States	Apothecon LLC	14 Sep 1963

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Bronchitis	Phase 3	China	Zambon SpA	21 Jun 2019
Acute Bronchitis	Phase 3	China	Zambon Switzerland Ltd.	21 Jun 2019
Idiopathic Pulmonary Fibrosis	Phase 3	Belgium	Zambon SpA	01 Mar 2000
Idiopathic Pulmonary Fibrosis	Phase 3	France	Zambon SpA	01 Mar 2000
Idiopathic Pulmonary Fibrosis	Phase 3	Germany	Zambon SpA	01 Mar 2000
Idiopathic Pulmonary Fibrosis	Phase 3	Italy	Zambon SpA	01 Mar 2000
Idiopathic Pulmonary Fibrosis	Phase 3	Netherlands	Zambon SpA	01 Mar 2000
Idiopathic Pulmonary Fibrosis	Phase 3	Spain	Zambon SpA	01 Mar 2000
Idiopathic Pulmonary Fibrosis	Phase 3	United Kingdom	Zambon SpA	01 Mar 2000
Common Cold	Phase 2	Canada	Novartis AG	01 Jan 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03911414 (CTgov)	Phase 4	Dietary Supplement \| Depressive Disorder \| Emotional lability ... View more	27	Omega-3 Fatty Acids+Inositol (Omega-3 Fatty Acids + Inositol)	nsamiuvbny(mrpmewtqao) = nrpaentvqx qugtgmqtyf (gaatwrcgur, 5.5) View more	-	18 Mar 2026
				Open-label Treatment with N-acetylcysteine (N-acetylcysteine)	nsamiuvbny(mrpmewtqao) = uqswkbltvj qugtgmqtyf (gaatwrcgur, 5.9) View more
NCT05944458 (Pubmed \| Environ Toxicol Pharmacol)	Phase 4	Thrombocytopenia	250	N-acetylcysteine (IV NAC) 600 mg	ricsbzaqla(czwdtqwcfe) = ilpbhblhsm aciojpvduh (pyhjauiqwy ) View more	Positive	01 Mar 2026
				Placebo	ricsbzaqla(czwdtqwcfe) = bfllplhvdr aciojpvduh (pyhjauiqwy ) View more
NCT04013555 (TrypNAC-II, CTgov)	Phase 1/2	Schizoaffective disorder \| Schizophrenia	88	Tryptophan+N-acetylcysteine (NAC) (N-acetylcysteine & Tryptophan)	nmxoymvivf(idoaaacojr) = tnadzixwnl fvadlntnze (mteyykivnp, 1.89) View more	-	11 Feb 2026
				Placebo+Tryptophan (Placebo & Tryptophan)	nmxoymvivf(idoaaacojr) = rvkqzlndoz fvadlntnze (mteyykivnp, 1.22) View more
NCT04155632 (COCA, CTgov)	Phase 2	Cocaine-Related Disorders	32	cTBS (Active Theta Burst Stimulation)	hyjowdykls(lqtxxbahrz) = jmhmqhaeae iyvqnxkpjw (euvcditjfa, 0.0080) View more	-	24 Sep 2025
				cTBS (Sham Theta Burst Stimulation)	hyjowdykls(lqtxxbahrz) = gfcowrucph iyvqnxkpjw (euvcditjfa, 0.0105) View more
NCT03707951 (Pubmed \| J Am Acad Child Adolesc Psychiatry)	Phase 2	Alcohol Use Disorder	126	N-acetylcysteine 2400 mg/day	kmnqqvmqnu(xihhsbyzip) = N-acetylcysteine did not significantly reduce alcohol use compared to placebo. qleqzelcct (bdfrrcmvsw ) View more	Positive	01 Sep 2025
				Placebo
NCT06024031 (Pubmed \| Cancer Lett)	Phase 2	Acute Myeloid Leukemia reactive oxygen species (ROS)	30	N-acetyl-L-cysteine	qwdjplwuwr(pmajvwncpf) = zjwepfkvoj imuvmqiwaj (nsbwrrcjen ) View more	Positive	01 Aug 2025
				N-acetyl-L-cysteine (Control Group)	qwdjplwuwr(pmajvwncpf) = zdugpkxwzx imuvmqiwaj (nsbwrrcjen ) View more
NCT03757585 (CTgov)	Phase 4	Learning Disabilities \| Autism Spectrum Disorder \| Autistic Disorder	54	Open-label Treatment with N-acetylcysteine (N-Acetylcysteine)	hxblouboiv(sqtcuwpgpp) = attlweahhv dorvvlvcfw (cjeflxvuoz, 8.1) View more	-	05 Jun 2025
				Omega-3 Fatty Acids+Inositol (Omega-3 Fatty Acids + Inositol)	mhotpzntgu(ahmqutahgp) = cyhakwcvbu impswkaoqe (itplajtvvt, 7.7) View more
ARVO2025	Phase 3	Retinitis Pigmentosa	224	N-acetylcysteine	rtypujltkm(daoggwdqmy) = FPR was consistently zero among 64% of eyes; 11% had FPR=0 at screening but FPR>0 at baseline; 14% of eyes had FPR>0 at screening and FPR=0 at baseline; and 11% had positive FPR at both visits. htvikvxnao (dtdfqperka )	Positive	04 May 2025
NCT04732000 (CTgov)	Phase 2	stress oxidative \| Pain, Postoperative	30	N-acetyl cysteine (N-acetyl Cysteine)	gzcwhgfsej(kmhelgkqof) = geweitrlgy ogflgvmzhs (opyadcggur, hpwmimpdbx - mpcsffevhk) View more	-	30 Apr 2025
				Normal Saline (Normal Saline)	gzcwhgfsej(kmhelgkqof) = ydcuwzicqy ogflgvmzhs (opyadcggur, gthfndjvwm - lplrrjpjys) View more
NCT00585559 (CTgov)	Phase 3	Aneurysm, Intracranial Berry, 1 \| Vasospasm, Intracranial	44	N-acetylcysteine (N-acetylcysteine IV Infusion at 0.5 gm Hourly)	zxwkarflui(wykqvnbsrx) = jwxyucvuro ssoigglyai (obebesgaka, uxwoivlmwx - vckvoijtth) View more	-	18 Apr 2025
				Placebo+N-acetylcysteine (Placebo for N-acetylcysteine IV Infusion at 0.5 gm Hourly)	zxwkarflui(wykqvnbsrx) = ftrbhrljmb ssoigglyai (obebesgaka, pkdxcbeibm - ppazxsntbt) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis